Calyxt, Inc. CLXT
We take great care to ensure that the data presented and summarized in this overview for Calyxt, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLXT
Top Purchases
Top Sells
About CLXT
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Insider Transactions at CLXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.4%
|
$2,300
$2.8 P/Share
|
|
Jan 07
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.34%
|
$3,450
$3.06 P/Share
|
|
Jan 06
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.29%
|
$3,450
$3.14 P/Share
|
|
Jan 03
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.24%
|
$2,300
$2.89 P/Share
|
|
Dec 31
2024
|
Rory B Riggs Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
1,388,084
+22.29%
|
-
|
|
Dec 31
2024
|
Rory B Riggs Chief Executive Officer |
SELL
Conversion of derivative security
|
Direct |
1,388,084
-100.0%
|
-
|
|
Dec 31
2024
|
Peter Beetham President and CEO |
BUY
Conversion of derivative security
|
Direct |
3,503
+0.91%
|
-
|
|
Dec 31
2024
|
Peter Beetham President and CEO |
SELL
Conversion of derivative security
|
Direct |
3,503
-100.0%
|
-
|
|
Dec 19
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.19%
|
$3,450
$3.45 P/Share
|
|
Dec 18
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.14%
|
$3,450
$3.75 P/Share
|
|
Dec 17
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.1%
|
$3,450
$3.85 P/Share
|
|
Dec 16
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.05%
|
$4,600
$4.06 P/Share
|
|
Dec 13
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-2.01%
|
$3,450
$3.87 P/Share
|
|
Dec 12
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.97%
|
$4,600
$4.08 P/Share
|
|
Dec 11
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.93%
|
$4,600
$4.35 P/Share
|
|
Dec 10
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.9%
|
$4,600
$4.43 P/Share
|
|
Dec 09
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.86%
|
$4,600
$4.15 P/Share
|
|
Dec 06
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.83%
|
$3,450
$3.86 P/Share
|
|
Dec 05
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.8%
|
$4,600
$4.0 P/Share
|
|
Dec 04
2024
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-1.76%
|
$4,600
$4.39 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 375K shares |
|---|---|
| Conversion of derivative security | 1.39M shares |
| Conversion of derivative security | 1.39M shares |
|---|---|
| Open market or private sale | 41.7K shares |